echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Novartis enters into a purchase agreement with Encore vision, Texas

    Novartis enters into a purchase agreement with Encore vision, Texas

    • Last Update: 2016-12-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Ding Xiangyuan said on December 22, 2016 that Novartis had reached a final agreement to acquire Encore vision, a company based in Fort Worth, Texas, which is committed to developing new treatments for presbyopia or hyperopia Relevant financial details are not disclosed Narasimhan, global head of Novartis, chief medical officer and drug development, said: "patients with presbyopia need innovative, effective and safe treatment options Currently, there is no treatment that can alleviate the disease On the other hand, according to an anonymous person familiar with the matter, Novartis started negotiations in November to acquire American generic manufacturer amneal for up to $8 billion, but the business failed and the incident was not disclosed Novartis and amneal did not respond to requests for comment Jimenez, chief executive of Novartis, is updating the group's drug portfolio to help the company restore sales growth The patent of Glivec, Novartis' best-selling drug, expires in the United States this year and in Europe next year, which puts pressure on sales just as generic drugs enter the market The world's largest prescription drug manufacturer has high expectations for experimental multiple sclerosis drugs, including baf312 and CJM 112, as well as the acquisition of ofatumumab from GlaxoSmithKline last year.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.